ICAN®—International Cancer Advocacy Network

In Cherished Memory
Susan Wojcicki, 1968 - 2024

ICAN and the Exon 20 Group deeply mourn the passing of Susan Wojcicki, entrepreneur, technology pioneer, humanitarian, and a leader in the war on cancer through the Troper Wojcicki Philanthropies.
More

Marcia Horn Discusses Advancements in EGFR Exon 20 Insertion+ NSCLC and the Importance of Community - AJMC

"Patients with EGFR exon 20 insertion have a very promising drug pipeline in addition to 2 critically important drug approvals. Few rare mutation groups see this so early on... "
More

Fistbump Fundraiser 2024 Highlights!

See photos from our major fundraiser honoring Exon 20 Group Founder Kevin Hanlon, supporting our research and advocacy projects! Donate Now!

ICAN^® is a 501(c)(3) patient advocacy and research advocacy organization with a small staff of professional advocates assisted by hundreds of volunteers worldwide. With our volunteer leadership representing 17 different time zones, we literally work around the clock, focusing on our Personalized Medicine Cancer Case Navigation Programs, health information technology issues, legislative initiatives, and research projects.

We aim to provide you with the best patient advocates and the most effective cancer patient advocacy possible, with the twin goals of working to extend your life with the highest quality of life.

ICAN^® advocates for you – the patient – or for the patient's spouse or family member who wants to manage the details of their loved one's cancer case with us.

We are beholden to no one – no oncology practice, no medical center, no clinical trial, and no biotech or pharmaceutical company.

Your case is unique and in our many years of non-stop advocacy services, we've never seen two patient cases remotely alike.

ICAN^® empowers you to navigate rapidly-expanding diagnostic and personalized treatment options. This information will assist you in informed discussions with family and providers.

We never, ever, compromise patient privacy (zealous implementers of HIPAA) – We will not disclose your name or any identifying information, or exploit your case for fundraising purposes.

ICAN is very grateful to Quint Studer for recognizing our patient services—and how we view patients—in his column that reaches tens of thousands of readers: Read Quint's article here.

In the News!

A New International Research Consortium to Battle Two Rare Cancer Mutations

In April 2016, Kevin Hanlon, an entrepreneur from Syracuse, New York, was diagnosed with an EGFR exon 20 insertion-mutated lung cancer. There are two types of exon 20 insertions, the other is a HER2 insertion. Both are rare gene mutations diagnosed in two percent of non-small cell lung cancer patients. Exon 20 insertions have also been found in 24 other cancers so far. Many of the patients diagnosed with these mutations are, like Hanlon, never-smokers in excellent shape....
— Marcia K. Horn JD, ICAN President and CEO and Exon 20 Group Executive Director

Published in The Future of Health (USA Today Mediaplanet digital supplement on Lung Health). Read the article

Watch a short video clip from Ellrose Hanlon, daughter of Exon 20 Group Co-Founder of cherished memory, Kevin Hanlon

Know Your Precise Cancer Diagnosis

If your oncologist cannot tell you what molecular subtype of cancer you have, then you may not have a specific diagnosis yet. And your surgical or biopsy tissue might not have been adequately profiled if your physician did not order comprehensive biomarker testing. Here's a pie chart, created by the brilliant Jacqulyne ("Jackie") Robichaux, PhD, member of the John V. Heymach, MD, PhD Laboratory and Assistant Professor at The University of Texas MD Anderson Cancer Center, which reveals the molecular subtypes of Non-Small Cell Lung Cancer. If you know your particular molecular subtype, treatment decisions will likely be more targeted. If comprehensive biomarker testing does not reveal a specific molecular subtype, then that's also important information for you and your oncologist to have.

Expand Chart InfoGraphic or select (PPTX) (Text Only) (JPG)

Guidestar Platinum Seal of Transparency 2021

ICAN, International Cancer Advocacy Network Nonprofit Overview and Reviews on GreatNonprofits

Volunteer. Donate. Review.

Federal Tax I.D.: EIN 86-0818253

Experience, Creativity, and Tenacity in the Patient's Battle Against Cancer